Hemla bra is a bispecific antibody created using our proprietary antibody modification technology. This drug binds active factor IX and factor X and replaces the cofactor function of factor VIII which is deficient or malfunctioning due to hemophilia A 3, 4). By weekly subcutaneous administration that can be self-injected, it is expected as an antibody drug that can inhibit bleeding in haemophilia A in which inhibitors have occurred. For haemophilia A who does not have an inhibitor, we apply for approval in April 2018.

As a leading company in biopharmaceuticals, Chugai will continue to contribute to the healthcare and people's health worldwide by creating innovative technological development and application of its technologies to respond to unmet medical needs.

Product names listed in the above text are protected by law.

that's all

Attach document information

Sales name: Hemla bra ® subcutaneous injection 30 mg, 60 mg, 90 mg, 105 mg, 150 mg

Generic name: emicizumab (genetically modified)

Indications: Inhibition of bleeding tendency in patients with congenital blood coagulation factor VIII deficient with blood coagulation factor VIII inhibitor

Dosage regimen · Dosage: Usually, 4 times per week at 3 mg / kg (body weight) as emicizumab (genetical recombination), subcutaneously 4 times subcutaneously, then 1.5 mg / kg (body weight) once a week at intervals Subcutaneously.

<Usage Precautions Related to Usage / Dosage>

This product should be used only for regular administration intended to control bleeding tendency and should not be administered for the purpose of hemostasis at bleeding.

Approval date: March 23, 2018

Drug price criterion Listing date: May 22, 2018

Sales start date: May 22, 2018

Expiration date: 2 years

Drug price:

Hemla bra ® subcutaneous injection 30 mg

Hemla bra ® subcutaneous injection Note 60 mg

Hemla bra ® subcutaneous injection 90 mg

Hemla bra® subcutaneous injection 105 mg

Hemla bra ® subcutaneous injection 150 mg